Please login to the form below
pneumococcal conjugate vaccine
This page shows the latest pneumococcal conjugate vaccine news and features for those working in and with pharma, biotech and healthcare.
Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab
Pfizer has launched a new study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) along with a booster dose of its BioNTech-partnered COVID-19 jab. ... 20vPnC includes capsular polysaccharide conjugates for the 13 serotypes in Pfizer’s
Latest news
-
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to
-
Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
its 15-valent pneumococcal conjugate vaccine candidate V114. ... For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our
-
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
New-generation shot could protect franchise from rival Merck &Co. Pfizer says it could be on course to file for approval of its new generation pneumococcal conjugate vaccine in the US ... Merck is hoping to muscle into Prevnar 13’s position in
-
Pfizer’s Prevnar-13 successor takes aim at Merck rival
Rivals look to broaden coverage across strains. Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after ... continue to build on our expertise in pneumococcal conjugate vaccines with this
-
Takeda's once-weekly DPP-4 inhibitor cleared in first market
The company also won Japanese approval for acne therapy Duac Combination Gel (clindamycin and benzoyl peroxide) and pneumococcal conjugate paediatric vaccine Synflorix. -
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Deal Watch table for March 2014
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
